Every 10-Q that Biomarin Pharmaceutical Inc (BMRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BMRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRN filings page.
BioMarin Pharmaceutical Inc. delivered Q2 2026 total revenues of $989.7 million, up from $825.4 million in 2025, driven by VOXZOGO, PALYNZIQ and newly acquired GALAFOLD and POMBILITI + OPFOLDA. Net income fell to $44.8 million (basic and diluted EPS $0.23) from $240.5 million as operating and financing costs rose.
Higher expenses included $73.5 million of intangible asset amortization, $63.3 million of interest expense and increased SG&A tied to the $5.3 billion Amicus acquisition and related restructuring. At June 30, 2026, cash and cash equivalents were $874.0 million, total debt principal was $4.3 billion, and operating cash flow for the first half of 2026 was $388.8 million.
BioMarin Pharmaceutical Inc. reported lower profitability for the quarter ended March 31, 2026 while preparing for a major acquisition. Total revenues were $766.2 million, up modestly from $745.1 million, driven by higher sales of VOXZOGO, NAGLAZYME, BRINEURA and other enzyme therapies, partly offset by declines in ALDURAZYME and ROCTAVIAN after its market withdrawal.
Cost of sales rose to $195.0 million, compressing gross margin to 74.5% from 79.7%, mainly due to a $31.0 million charge tied to an unsuccessful NAGLAZYME manufacturing campaign. Research and development expense increased to $178.8 million and selling, general and administrative expense to $258.3 million, reflecting pipeline expansion and Amicus pre-close costs. Net income declined to $105.5 million, or $0.54 per diluted share, from $185.7 million.
Cash, cash equivalents and restricted cash equivalents increased to $3.07 billion, helped by liquidating investments and issuing $850.0 million of 5.5% senior notes due 2034, partly held in escrow. After quarter-end, BioMarin closed the approximately $4.8 billion all-cash acquisition of Amicus, adding GALAFOLD, POMBILITI + OPFOLDA and Phase 3 asset DMX-200, funded with cash on hand and new $2.8 billion term loans plus a $600.0 million revolving credit facility, significantly increasing long-term debt obligations.
BioMarin Pharmaceutical Inc. reported Q3 2025 results showing steady sales but a GAAP loss driven by R&D charges. Total revenue was $776.1 million, up from $745.7 million a year ago. Product leaders were VOXZOGO $218.4M, VIMIZIM $182.8M, and PALYNZIQ $108.8M; ALDURAZYME delivered $53.7M and ROCTAVIAN $3.2M.
Operating expenses rose to $822.8 million as R&D reached $409.5M, reflecting a $221.0M acquired in-process R&D charge tied to the Inozyme transaction. The quarter posted a net loss of $30.7M (diluted EPS $(0.16)) versus net income of $106.1M (EPS $0.55) last year. Year‑to‑date, revenue was $2,346.7M with net income $395.5M (diluted EPS $2.04), supported by operating cash flow of $728.4M.
Liquidity remained strong with cash and cash equivalents $1,250.1M, short‑term investments $227.7M, and long‑term investments $512.9M. Total assets were $7.61B. The company has $600.0M of 1.25% convertible notes due 2027. BioMarin completed the Inozyme acquisition (total consideration $329.1M), adding late‑stage enzyme therapy BMN 401; management also plans to pursue options to divest ROCTAVIAN.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.